Description
Retatrutide peptide is an investigational synthetic peptide designed as a single-molecule agonist of three hormone receptor systems: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors. It is also known by the research designation LY3437943. Published clinical research describes retatrutide as a triple-hormone-receptor agonist, while Eli Lilly continues to classify it as an investigational molecule undergoing clinical development.
Retatrutide research examines how simultaneous activation of GIP, GLP-1, and glucagon receptors affects metabolic and endocrine signaling. Current retatrutide peptide research also provides a framework for investigating receptor pharmacology, glucose-related pathways, energy regulation, and interactions among three distinct hormone-signaling systems. Because retatrutide remains investigational, research findings should not be presented as established therapeutic outcomes or as support for unsupervised human use.
Features
- Composition: Synthetic triple-hormone-receptor agonist peptide
- Research Code: LY3437943
- Receptor Targets: GIP, GLP-1, and glucagon receptors
- Research Classification: Triple receptor agonist
- Research Focus: Metabolic signaling, receptor pharmacology, endocrine pathways, and energy-related mechanisms
- Development Status: Investigational compound undergoing clinical research as of 2026
- Format: Supplied as lyophilized research material
- Laboratory Application: Controlled peptide and receptor-signaling studies
- Recommended Storage: −20 °C unless otherwise stated in batch-specific documentation
Disclaimer: Supplied strictly for laboratory research. Not intended for human or veterinary use, administration, consumption, diagnosis, treatment, or therapeutic purposes.
Reviews
There are no reviews yet.